Centessa Pharmaceuticals (CNTA) Common Equity: 2022-2025
Historic Common Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $301.6 million.
- Centessa Pharmaceuticals' Common Equity fell 39.58% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 39.58%. This contributed to the annual value of $401.5 million for FY2024, which is 69.97% up from last year.
- Centessa Pharmaceuticals' Common Equity amounted to $301.6 million in Q3 2025, which was down 12.57% from $344.9 million recorded in Q2 2025.
- In the past 5 years, Centessa Pharmaceuticals' Common Equity registered a high of $499.1 million during Q3 2024, and its lowest value of $215.2 million during Q1 2024.
- In the last 3 years, Centessa Pharmaceuticals' Common Equity had a median value of $293.3 million in 2023 and averaged $318.3 million.
- Per our database at Business Quant, Centessa Pharmaceuticals' Common Equity skyrocketed by 92.43% in 2024 and then crashed by 39.58% in 2025.
- Centessa Pharmaceuticals' Common Equity (Quarterly) stood at $336.2 million in 2022, then fell by 29.72% to $236.2 million in 2023, then spiked by 69.97% to $401.5 million in 2024, then plummeted by 39.58% to $301.6 million in 2025.
- Its Common Equity stands at $301.6 million for Q3 2025, versus $344.9 million for Q2 2025 and $386.2 million for Q1 2025.